The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial

Ähnliche Einträge

• Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes
  von: Ebaa Al‐Ozairi, et al.
  Veröffentlicht: (2024)
• Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes
  von: Ebaa Al Ozairi, et al.
  Veröffentlicht: (2025)
• Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
  von: Stergios A. Polyzos, et al.
  Veröffentlicht: (2026)
• A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada
  von: James Kim, et al.
  Veröffentlicht: (2025)
• Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
  von: Matthew J. Armstrong, et al.
  Veröffentlicht: (2024)